News About: R&D


“Once remote medicine dispensers are implemented, they will eventually be managed by call centers”

“If the door of remote medicine dispenser opens, the function of pharmacists will be destroyed. Even though there will be lots of restrictions soon, it will be spoiled in various forms through future law amendments, w...

Clear opinion differences between Sanofi vs LG over ‘Zemiglo’

The outline of the lawsuit over ‘Zemiglo,’ an antidiabetic developed by LG Life Sciences, became visible.   The first defense for the damage suit filed by the previous seller of Zemiglo, Sanofi-Aventis Korea, against...

Multiple myeloma therapy, ‘Kyprolis’ conducted Phase 3 clinical trials on Koreans

The new multiple myeloma therapy, ‘Kyprolis(carfilzomib, Amgen),’ will start a Phase 3 clinical trial adding 16 Korean subjects. It has attracted interests of the industry since it is a newly-approved clinical trial ...

Next-generation dementia therapy’s Phase 3 clinical trials starts in Korea

The next generation dementia therapy, which was expected to generate approximately KRW 1 trillion prescriptions in the global market, was approved to conduct Phase 3 clinical trials in Korea. The therapy is ‘RVT-101’...

Celltrion starts global Phase 3 clinical trials on Remsima’s SC type

In order to secure competitiveness in the TNF-α inhibitor(autoimmune disease therapy) market, Celltrion will start the global Phase 3 clinical trial of the Remsima’s SC type(sub...

Arguments about Sanofi’s Menactra clinical trials for children

Since Sanofi-Pasteur’s ‘Menactra,’ a competing product of the GSK’s top meningococcal meningitis vaccine in Korea, ‘Menveo,’ has been conducted for clinical trials to extend ind...

Korea Drug Development Fund to conclude joint anticancer R&D agreement

The Korea Drug Development Fund(Head Sang-Un Joo, hereinafter referring to KDDF) will start the ‘BigPharma Joint R&D Program’ in regards of anticancer development researches. On the 8th, the KDDF announced it conclu...

Osong & Daegu Medical Innovation Foundations’ cooperation with largest European BioCluster

On the 5th, Osong Medical Innovation Foundation(Chief Director Kyung Sun) and Daegu Gyeongbuk Medical Innovation Foundation(Chief Director Jae-tae Lee) announced conclusion of the Strategic Exploratory Agreement(SEA) ...

Extended tax deductions for new drug R&Ds

In order to foster new industries, the government decided to apply tax deduction even for expenses of Phase 3 clinical trials that are conducted in Korea. Moreover, it also decided to raise the ‘New Industry Fosterin...

7 pharmaceutical companies to spend more than KRW 50 billion into R&D

Among listed pharmaceutical companies, there were 7 companies which invested more than KRW 50 billion into R&D expenses last year, including Hanmi Pharm and Green Cross. Moreover, although many companies seem to acti...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.